Abstract
Hepatitis C virus (HCV) is the major cause of chronic liver disease worldwide. There is evidence that neutralizing anti-HCV antibodies may find potential applications in novel prophylactic and therapeutic strategies. This paper describes the very high neutralization activity and unique biological features of two broadly cross-reactive and cross-neutralizing anti-HCV human monoclonal IgG1 derived from human monoclonal recombinant Fab fragments.
MeSH terms
-
Antibodies, Monoclonal / chemistry
-
Antibodies, Monoclonal / genetics
-
Antibodies, Monoclonal / immunology*
-
Hepacivirus / chemistry
-
Hepacivirus / genetics
-
Hepacivirus / immunology*
-
Hepatitis C / immunology*
-
Hepatitis C / virology
-
Hepatitis C Antibodies / chemistry
-
Hepatitis C Antibodies / genetics
-
Hepatitis C Antibodies / immunology*
-
Humans
-
Immunoglobulin Fab Fragments / chemistry
-
Immunoglobulin Fab Fragments / genetics
-
Immunoglobulin Fab Fragments / immunology*
-
Immunoglobulin G / chemistry
-
Immunoglobulin G / genetics
-
Immunoglobulin G / immunology*
-
Kinetics
-
Neutralization Tests
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / immunology*
Substances
-
Antibodies, Monoclonal
-
Hepatitis C Antibodies
-
Immunoglobulin Fab Fragments
-
Immunoglobulin G
-
Viral Envelope Proteins
-
glycoprotein E2, Hepatitis C virus